Notable Stocks: Vale SA, New Oriental Education & Tech Grp, Exterran Holdings, Myriad Genetics

Lakeway, TX -- (SBWIRE) -- 03/05/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Vale SA (ADR)(NYSE:VALE) shares fell 2.86% to $18.02.The Company, on Feb. 18, annluced that it has declared force majeure (FM) on a number of its coal sales contracts as on February 15, 2013 and is communicating with customers as required under its agreements with them. So far, the Company estimates a loss of approximately 250,000 metric tons in metallurgical coal shipments. It will disclose further information related to the evolution of these events until the situation has been normalized.

How Should Investors Trade VALE After The Recent Movement? Find Out Here

New Oriental Education & Tech Grp (ADR) (NYSE:EDU) shares decreased 2.84% and closed at $15.07. The 52 week trading range for the company is $9.41 - $29.19. The company is a provider of private educational services in China based on the number of program offerings, total student enrollments and geographic presence.

Is EDU Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Exterran Holdings, Inc. (NYSE:EXH) shares decreased 2.83% and closed at $25.04 in the last trading session. The company, on Feb. 26, posted pre-tax loss for the period of $24.68 million, wider than the prior-year period's pre-tax loss of $23.91 million. Thus, the firm reported net loss attributable to shareholders of $5.73 million versus a loss of $66.57 million last year. On a per share basis, loss posted by the company amounted to $0.09 versus a loss of $1.06 last year. Analysts estimated earnings per share of $0.02 for the quarter. Revenue for the three months witnessed a surge at $838.92 million, up from $689.06 million last year and was well above consensus estimate of $721.30 million.

Is EXH a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Myriad Genetics, Inc. (NASDAQ:MYGN) shares fell 2.83% to $24.74. The company’s Australian court victory recognizing its ownership of patents for genes linked to cancer risks will be appealed by a group representing cancer patients, a law firm said yesterday. The issue has divided the global medical community, with groups including the Association for Molecular Pathology and the American College of Medical Genetics arguing that Myriad is trying to get legal ownership of parts of the human body.
Additionally, analysts at Jefferies & Co. decreased their price target on shares of MYGN from $33.00 to $31.00 in a research report issued to clients and investors yesterday. The firm currently has a “buy” rating on the stock.

How Should Investors Trade MYGN After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.